14 results about "Monoamine oxidase" patented technology

The invention belongs to the technical field of biological medicine analysis, and particularly relates to a fluorescent probe sequentially responding to gamma-glutamyltranspeptidase and monoamine oxidase and application of the fluorescent probe. The structure of the fluorescent probe is as shown in a formula 1, the fluorescent probe in the formula 1 is constructed by sequentially covalently connecting gamma-glutamyltranspeptidase and specific recognition groups of monoamine oxidase and integrating the gamma-glutamyltranspeptidase and the specific recognition groups of monoamine oxidase into a benzothiazole-xanthene fluorescent parent structure, and the fluorescent probe has near-infrared fluorescence luminescence performance. The probe adopts a double enzyme response activation strategy, and can be activated and generate a fluorescence signal only when gamma-glutamyltranspeptidase and monoamine oxidase exist at the same time, so that the fluorescence probe is high in specificity and has excellent accuracy and specificity in the aspects of pathological imaging, drug safety evaluation and the like.

The invention provides a monoamine oxidase mutant, recombinant yarrowia lipolytica and application of the monoamine oxidase mutant and the recombinant yarrowia lipolytica. Monoamine oxidase is subjected to site-directed mutagenesis modification by searching a key catalytic pocket, so that the catalytic efficiency of monoamine oxidase is improved, and biosynthesis of bovine heart alkali is increased; finally, the Phe208Ala mutant is obtained, and the capacity of synthesizing bovine heart alkali by utilizing a genetic engineering strain constructed by the mutant is obviously improved; an MAO-A wild type and a MAO-A mutant are respectively expressed and designed in engineering bacteria, the ability of the mutant for catalyzing dopamine to generate bovine heart alkali in yarrowia lipolytica is compared, and the result shows that the monoamine oxidase mutant can significantly improve the yield of the yarrowia lipolytica bovine heart alkali, the yield is significantly improved by 40.05% compared with an original strain, and the monoamine oxidase mutant has a good application prospect. The method has better performance, can significantly improve the yield of biosynthesized phylline, is more suitable for industrial application in the future development process, and can significantly reduce the production cost and improve the production efficiency.

The present invention provides novel biocatalysts and associated methods of use for the oxidative desymmetrization of fused bicyclic proline analogues to produce APIs and intermediates. The novel biocatalysts of the present disclosure are engineered monoamine oxidase enzymes with improved solubility, thermostability, and activity on fused bicyclic proline compounds, as compared to a reference monoamine oxidase. In particular, the engineered monoamine oxidase enzymes of the present disclosure require reduced enzyme loading for the manufacturing of APIs and intermediates, as compared to a reference monoamine oxidase enzyme.

This invention provides a novel MAO-B inhibitor containing a tetrahydronaphthalene-1-amine structure, its preparation and uses, belonging to the pharmaceutical field. The derivative is a compound represented by Formula I, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The compound of this invention can be used to inhibit monoamine oxidase (MAO), particularly selectively inhibiting MAO-B; it has promising applications in the treatment of Parkinson's disease, Alzheimer's disease, mood disorders, and other diseases.

The application discloses pigeon blood antioxidant and anti-aging active peptide and a preparation method and application thereof. The preparation method of the pigeon blood antioxidant and anti-aging active peptide comprises the following steps: adding an anticoagulant to pigeon blood and performing hemolysis pretreatment to dissolve pigeon blood hemoglobin; after the pretreatment, deionized water is added, the blood-water ratio and pH value are adjusted, a protease is added for enzymolysis, the enzyme is inactivated after the enzymolysis is completed, the temperature is cooled to room temperature, the pH value is adjusted to 7.0, and centrifugation is performed to obtain supernatant, and pigeon blood enzymolysis polypeptide is obtained after drying; and the protease is pepsin or trypsin. The pigeon blood active polypeptide prepared by the application can realize the antioxidant and anti-aging effects by adjusting the levels of oxidative stress, monoamine oxidase (MAO), advanced glycation end products (AGEs) and Klotho protein of an aging-regulating gene in brain tissues of D-galactose-induced aging mice.

Provided in the present invention are preparation and use of a novel MAO-B inhibitor containing a tetralin-1-amine structure, which belong to the field of medicines. The derivative is a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The compound of the present invention can be used for inhibiting monoamine oxidase (MAO), especially selectively inhibiting MAO-B. The compound can be used for treating diseases such as Parkinson's disease, Alzheimer's disease, and emotional disorders, and exhibits good application prospects.

This invention provides a monoamine oxidase mutant and a recombinant *Yarrowia lipolytica* strain, along with their applications. By identifying key catalytic pockets, site-directed mutagenesis was performed on the monoamine oxidase to improve its catalytic efficiency and increase the biosynthesis of calciferine. The Phe208Ala mutant was ultimately obtained, and the genetically engineered strain constructed using this mutant showed a significantly enhanced ability to synthesize calciferine. The wild-type MAO-A and the designed MAO-A mutant were expressed in the engineered strain, and their ability to catalyze the conversion of dopamine to calciferine in *Yarrowia lipolytica* was compared. The results showed that the monoamine oxidase mutant significantly increased the yield of calciferine in *Yarrowia lipolytica*, with a 40.05% increase compared to the starting strain. This improved performance significantly enhances the biosynthetic yield of calciferine and is more suitable for industrial applications in the future, potentially reducing production costs and increasing production efficiency.

The invention belongs to the technical field of biological medicines, and particularly relates to a substituted coumarin-benzoxazole derivative as well as a preparation method and application thereof. The derivative has a structure shown in a formula (I) or (II), R1 is selected from hydrogen, methyl, chlorine and formyloxyethyl, R2 is selected from hydrogen, methyl, trifluoromethyl and a benzene ring, and n is a positive integer ranging from 2 to 5. The preparation is realized through two-step substitution reaction, raw materials are cheap, the process is simple and convenient, and the method is suitable for industrial production. The derivative has remarkable multi-target activity, can inhibit monoamine oxidase-B and beta-amyloid protein aggregation and butyrylcholine esterase at the same time, has a good antioxidant effect, can effectively improve pathological injuries related to neurodegenerative diseases, and is low in biotoxicity and high in safety. The invention can be used for preparing drugs for treating Alzheimer's disease, Parkinson's disease and other diseases, provides a new efficient candidate molecule for the treatment of related diseases, and has important medical research value and market application prospect.

The invention discloses a substituted coumarin-eugenol derivative as well as a preparation method and application thereof. The derivative is prepared by connecting a coumarin mother nucleus and eugenol through a flexible chain by virtue of a two-step nucleophilic substitution reaction. The derivative disclosed by the invention is novel in structure, can simultaneously and effectively inhibit monoamine oxidase-B and acetylcholin esterase and inhibit A beta protein aggregation, has excellent oxidation resistance and metal ion chelation capability, and realizes a multi-target synergistic effect. In-vitro and in-vivo experiments show that the compound has a remarkable improvement effect on a plurality of pathological links such as Alzheimer's disease, and is low in neurotoxicity and high in safety. Meanwhile, the preparation method has the advantages of easily available raw materials and simple steps, is suitable for industrial production, and has a wide application prospect in the aspect of preparing the anti-neurodegenerative disease medicine.

Disclosed are a genetically engineered bacterium catalyzing the production of a quinoline compound, and a use thereof. The genetically engineered bacterium expresses monoamine oxidase and an enzyme capable of catalyzing alcohol oxidation, the enzyme capable of catalyzing alcohol oxidation being selected from alcohol oxidase or alcohol dehydrogenase. It has been unexpectedly discovered that monoamine oxidase coupled to alcohol dehydrogenase or alcohol oxidase can catalyze the preparation of quinoline from amino alcohol substrates, which fills the gap that current biocatalysis methods cannot synthesize amino alcohol substrates into quinoline compounds.

The invention relates to a preparation method and application of a monoamine oxidase treating fluid. The preparation method comprises the following steps: step 1, preparing a buffer solution; step 2, preparing an enzyme inclusion solution; and step 3, sequentially adding 0.25 g / L-0. 5 g / L of flavin adenine dinucleotide and 0.25 g / L-0. 5 g / L of a hydrophilic nonionic surfactant into the continuously stirred enzyme inclusion solution in an environment of 4 + / -1 DEG C, continuously stirring for 30 minutes, filtering, transferring into a dark brown glass bottle, and storing at 2-8 DEG C, thereby obtaining the product. The method disclosed by the invention has the beneficial effects that 1, the problem of too fast enzyme activity loss in the preparation process of the MAO quality control product is solved, and the enzyme activity loss is reduced from original 40% to below 10%; 2, the problem of short preservation period after the MAO quality control product is redissolved is solved, the preservation stability at 2-8 DEG C after the MAO quality control product is redissolved is improved to 7 days from the original 7 hours, and the frozen preservation at-20 DEG C is improved to 30 days from 10 days; and 3, the risk of too high production cost or patent infringement of reagent enterprises caused by MAO raw materials prepared by adopting patented technologies such as gene modification is avoided.

The invention relates to the field of nanometer material development and nanometer biological medicine and pharmacology, in particular to monoamine oxidation self-polymerization nanoparticles as well as a preparation method and application thereof. The preparation method of the monoamine oxidation self-polymerization nanoparticles comprises the following steps: sequentially adding a tween-80 solution, a 5-HT solution and an alkaline buffer solution into purified water in a water bath at 50-70 DEG C, stirring at 800-1200 rpm, and centrifuging to obtain the monoamine oxidation self-polymerization nanoparticles. The nanoparticles have free radical scavenging capacity, and the scavenging efficiency is in direct proportion to the concentration. After the 5-HT micromolecules are oxidized and self-polymerized to form the nanoparticles, the in-vivo cytotoxicity of the nanoparticles can be remarkably reduced, the biocompatibility is improved, and meanwhile, the nanoparticles have the capabilities of remarkably promoting cell proliferation and migration, inhibiting inflammation-induced cell apoptosis and regulating and controlling the cell cycle. The nanoparticles can also be used as a carrier to be combined with other drugs.

The application belongs to the technical field of traditional Chinese medicine, and discloses a kind of smelling and transdermal double-acting smoke control compound acupoint massage essential oil and preparation method thereof, the essential oil takes cinnamon essential oil as monarch drug, chamomile essential oil as ministerial drug, takes peppermint essential oil, limonene, linalool, vanillin, methyl cinnamate as auxiliary drug, and adds vitamin E, rosemary extract, eucalyptol, rose essential oil as auxiliary component.The application solves the core defects of existing essential oil smoke control products through scientific compatibility and process optimization, and each component synergistically inhibits monoamine oxidase activity and regulates dopamine level.Combined with traditional Chinese medicine acupoint massage and nasal smelling double absorption pathway, rapid effect and long-acting smoke control effect are achieved.The application solves the problems of poor user experience, poor stability, slow effect and insufficient targeting of existing smoke control essential oil, has the advantages of good smoke control effect, convenient use, wide applicability, high user acceptance and the like, and is beneficial to improving the success rate of smoking cessation.

The invention discloses a phenol derivative with multi-target neuroprotection activity as well as a production strain and application thereof. Two phenol natural products with novel structures are separated from an acacia confusa endophytic fungus Diaporthe hubeiensis ZMU-49-3 for the first time. In-vitro activity research shows that the compound has clear ABTS free radical scavenging capacity and monoamine oxidase (MAO-A / MAO-B) dual inhibition activity. The compound is simple in structure and small in molecular weight, can be used as a drug lead compound or a bioactive reference substance, is used for research, development and screening of anti-oxidation and neurodegenerative disease (such as Alzheimer's disease) related drugs, and has important scientific research value and application prospect.